CLAL BIOTECHNOLOGY INDUSTRIES LTD. Clal Biotechnology Industries Ltd. Share Price
Equities
CBI
IL0011042806
Investment Holding Companies
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.5 ILa | +5.32% |
|
+2.37% | +19.65% |
| Sales 2022 | 370K 99.13K 37M 7.93M | Sales 2023 | 104K 27.86K 10.4M 2.23M | Capitalization | 62.27M 16.68M 6.23B 1.33B |
|---|---|---|---|---|---|
| Net income 2022 | -61M -16.34M -6.1B -1.31B | Net income 2023 | -31M -8.31M -3.1B -664M | EV / Sales 2022 | 331 x |
| Net Debt 2022 | 23.85M 6.39M 2.38B 511M | Net Debt 2023 | 22.4M 6M 2.24B 480M | EV / Sales 2023 | 814 x |
| P/E ratio 2022 |
-1.6
x | P/E ratio 2023 |
-2.01
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.65% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.32% | ||
| 1 week | +2.37% | ||
| Current month | +13.37% | ||
| 1 month | +13.37% | ||
| 3 months | +24.02% | ||
| 6 months | +7.22% | ||
| Current year | +19.65% |
1 week
44.50
48.00
1 month
41.0048.00
Current year
36.6049.70
1 year
36.6065.00
3 years
36.60267.80
5 years
36.60293.70
10 years
36.60980.00
| Managers | Title | Age | Since |
|---|---|---|---|
Assaf Segal
CEO | Chief Executive Officer | 51 | 30/06/15 |
Liat Nissan
DFI | Director of Finance/CFO | 46 | - |
Arnon Aharon
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 08/05/03 | |
Yuval Yanai
BRD | Director/Board Member | 71 | 17/11/15 |
Gad Keren
BRD | Director/Board Member | 73 | 16/02/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 47.5 | +5.32% | 142 229 |
| 25/04/24 | 45.1 | -2.80% | 16,816 |
| 24/04/24 | 46.4 | +3.57% | 17,970 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 30, 2024 at 03:24 pm
More quotes
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
| 1st Jan change | Capi. | |
|---|---|---|
| +19.65% | 18.83M | |
| +16.98% | 76.16B | |
| +59.45% | 17.61B | |
| +2.74% | 15.94B | |
| +8.60% | 14.05B | |
| -0.04% | 12.4B | |
| +8.96% | 12.06B | |
| +5.82% | 10.89B | |
| +34.35% | 10.34B | |
| -1.92% | 9.75B |
- Stock Market
- Equities
- CBI Stock
